NCODA Spring Forum 2020 Transitions to Virtual E-Meeting

March 10, 2020 3pm Eastern

To our valued members and corporate partners,

In alignment with our Guiding Values, 1) Patient-Centered and 2) Always Collaborative, NCODA is taking all necessary precautions in order to provide our members and corporate partners a value-added experience, while remaining vigilant concerning the health and safety concerns surrounding the coronavirus outbreak.

Our top priority is the health and safety of our patients, members, exhibitors, and meeting faculty. We have a moral and professional obligation to do what we can individually and collectively to minimize the spread of this outbreak. It’s about keeping oncology patients safe. They are immunocompromised and many have comorbidities; our responsibility is to abide by the policies and procedures created to ensure the safety of patients.

Therefore, we have made the decision to cancel the 2020 NCODA Spring Forum in Dallas, Texas (March 18-20). We understand that our meetings provide members and partners with updates and sharing of best practices, and we realize participants get firsthand information that they can use to enhance care at their respective practices.

When important meetings, like the NCODA Spring Forum, get canceled it’s a major disruption in dissemination of vital information. Keeping this in mind, NCODA will be converting the Spring Forum into an e-meeting format that will take place on Thursday, March 19th from 8am – 6pm eastern. All registered participants will be contacted via email with the necessary e-meeting sign-in details.

NCODA is committed to fulfilling our Mission of disseminating critical oncology information. We intend to provide a rich alternative meeting and learning experience for the oncology community. We will provide more information about cancellation logistics, including registration, hotel, and flight accommodations, in the near future. Please stay tuned for more information. See the full press release here.

Please email Kristen Ray ( with any questions.

Read More


January 27, 2020


NCODA Announces the defining of the

Medically Integrated Dispensing Pharmacy


Cazenovia, NY – The National Community Oncology Dispensing Association, Inc. (NCODA) is pleased to announce we have conclusively defined the Medically Integrated Dispensing Pharmacy. This definition serves to empower the NCODA membership to fulfill their cancer care Mission.

What is a Medically Integrated Dispensing (Pharmacy)?

A dispensing pharmacy within an oncology center of excellence that promotes a patient-centered, multidisciplinary team approach. The MID is an outcome-based collaborative and comprehensive model that involves oncology health care professionals and other stakeholders who focus on the continuity of coordinated quality care and therapies for cancer patients.

For more information about NCODA’s Mission and initiatives to support the Medically Integrated Dispensing Pharmacy visit: or read the official release here.

Read More


April 26, 2019

Barry D. Brooks, M.D., Joins NCODA Executive Council


Cazenovia, NY – The National Community Oncology Dispensing Association, Inc. (NCODA)is pleased to announce the addition of Barry D. Brooks, M.D. to their Executive Council. Dr. Brooks joined the Council in April.

Barry D. Brooks, M.D., is a hematologist and medical oncologist with Texas Oncology and for 17 years has worked as physician-lead on the Drug Contracting committee of US Oncology. He was Chair of P&T from 2011 to 2018 and now serves as Medical Director of Oral Oncolytics for USON. He is the author of many publications and abstracts in the field of oncology. ”Being part of NCODA is a great honor. I believe NCODA will do for oncology dispensing what COA has done for community oncology by improving access to oral oncology drugs for America’s cancer patients and giving patients a voice in Washington. ”, said Dr. Brooks.

“Dr. Brooks, in addition to being an outstanding medical oncologist, is a dynamic individual who will bring a great deal of insight from a physician’s perspective to our NCODA initiatives” said Jim Schwartz, NCODA President and Executive Council Chair.

For more information about NCODA’s Executive Council and general updates visit or read the official release here.

Read More


March 29, 2019

Cazenovia, NY – The National Community Oncology Dispensing Association, Inc. (NCODA)is pleased to announce the addition of three new members to the Executive Council. Randy Erickson, RN, BSN, MBA, James Gilmore, PharmD, and Kirollos Hanna, PharmD, BCPS, BCOP joined the Council in March.

Randy Erickson currently serves as Chief Executive Officer at Utah Cancer Specialists in Salt Lake City, UT. He is a skilled healthcare professional with over 20 years of clinical experience. In his current role as CEO, Randy helps set the strategic course for the practice. Utah Cancer Specialists is the largest community-based oncology and hematology treatment practice in Utah, with physicians providing medical oncology, hematology, radiation oncology, and imaging services. ”Cancer care has become increasingly complex and with more oral therapies available, providing high quality care to our patients has never been more important. The overall patient experience is enhanced when physicians are able to dispense these medications within their own practices. NCODA is the perfect partner in helping practices improve pharmacy operations and enhance patient care,” said Randy. 

James Gilmore is the Executive Vice President at Georgia Cancer Specialists (GCS). GCS is a national leader in advanced cancer treatment and research. Their 50 physicians provide care in 26 Northside Hospital Cancer Institute locations across Metro Atlanta, and North and Central Georgia. ”I am very honored to serve on the Executive Council of NCODA. It has become one of the most important organizations in the oncology space. I look forward to helping NCODA to continue to grow and to ensure that our patients have access to live-saving therapies for years to come”, said Gilmore. 

Kirollos Hanna is board certified by the Board of Pharmacy Specialties in Oncology Pharmacy and Pharmacotherapy. He is currently an Assistant Professor of Pharmacy at the Mayo Clinic College of Medicine. He primarily practices Hematology/Oncology pharmacy at the University of Minnesota Medical Center and Mayo Clinic. ”It is an honor and privilege to serve patients through NCODA. The rapid growths in oral oncology therapeutics and practices have created large gaps in optimizing care and streamlining dispensing. As a firm believer in the NCODA mission of a patient-centered, medically-integrated dispensing model, I will continue to advocate for patients and best-practice initiatives”, said Hanna. Kirollos is an active member in NCODA committees and initiatives. He serves on the advisory board for the Treatment Support Kit (TSK) initiative, he is editor for the Positive Quality Intervention (PQI) initiative, he is serves on the oral chemotherapy education (OCE) steering committee, and he also serves as part of the editorial board for NCODA’s publication, Oncolytics Today.

“Over the last month we have added three highly skilled and well-respected oncology professionals to our Executive Council!” said Jim Schwartz, NCODA President and Executive Council Chair. “Randy, James, and Kirollos are well positioned to help us continue executing on our mission.”

For more information about NCODA’s Executive Council and general updates visit

See the Full Press Release HERE

Read More


March 15, 2019

NCODA Announces Dr. Mario Lacouture as Director of the Medical Advisory Board for Treatment Support Program

Cazenovia, NY – The National Community Oncology Dispensing Association, Inc. (NCODA) Executive Council is pleased to announce that Mario Lacouture, M.D. will be joining the Treatment Support Program as Director of the Medical Advisory Board.

Dr. Lacouture is a board-certified dermatologist at Memorial Sloan Kettering Cancer Center in New York City, where he serves as Director of the Oncodermatology Program. Dr. Lacouture’s clinical career has focused on the recognition and management of side effects resulting from cancer treatments, affecting the skin, hair, and nails of cancer patients and survivors.

“It is a great day for NCODA!” proclaimed Michael Reff, Founder and Executive Director of NCODA, after learning that Mario Lacouture would be joining the Treatment Support Program team. Dr. Lacouture will start his work with the program in March. In his role as Director of the Medical Advisory Board, Dr. Lacouture will be providing expertise and guidance to the program committee.

The mission of NCODA’s Treatment Support Program is to provide patients and caregivers with resources that make sense for adherence and adverse effect management during treatment with anticancer medications. The priority is to equip healthcare professionals and patients with educational information and products that will be needed during the course of treatment. NCODA’s Treatment Support Kits are a fundamental component of the program.

TSK committee co-chairs Chris Kepinski, PharmD [Southern Oncology Specialists, NC] and Jamie Fritz, PharmD [Compass Oncology, WA] also see Dr. Lacouture as a great asset to the program. “Having an expert on the team who has seen first-hand how adverse effects of cancer treatments impact patient adherence is extremely important,” Kepinski said.

“The work that NCODA is doing with the Treatment Support Program is something that I fully support,” said Lacouture. “What better way to help patients than by providing them with the information and products they need to maintain their quality of life and health throughout their treatment course.”

For more information about NCODA’s Treatment Support Program visit:

See Full Press Release Here.

Read More